JAKs go nuclear: Emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth

JAK2V617F-Mediated Phosphorylation of PRMT5 Downregulates Its Methyltransferase Activity and Promotes Myeloproliferation

(2011) Fan Liu et al.   CANCER CELL

Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond

(2011) Alfonso Quintás-Cardama et al.   NATURE REVIEWS DRUG DISCOVERY

Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control

(2011) H Jäkel et al.   ONCOGENE

Analysis of Jak2 Catalytic Function by Peptide Microarrays: The Role of the JH2 Domain and V617F Mutation

(2011) Arturo Sanz et al.   PLoS One

Tyrphostin AG490 reduces NAPDH oxidase activity and expression in the aorta of hypercholesterolemic apolipoprotein E-deficient mice

(2011) Ioana M. Fenyo et al.   VASCULAR PHARMACOLOGY

Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia

(2010) C. R. Rinaldi et al.   BLOOD

Nuclear Janus-Activated Kinase 2/Nuclear Factor 1-C2 Suppresses Tumorigenesis and Epithelial-to-Mesenchymal Transition by Repressing Forkhead Box F1

(2010) J. Nilsson et al.   CANCER RESEARCH

Prolactin-induced Jak2 phosphorylation of RUSH: A key element in Jak/RUSH signaling

(2010) Rebecca A. Helmer et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Genetic factors in chronic inflammation: Single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population

(2010) Lynnette R. Ferguson et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease

(2010) Dean S. Griffiths et al.   NATURE CELL BIOLOGY

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

(2010) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK redux: a second look at the regulation and role of JAKs in the heart

(2009) Mazen Kurdi et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment

(2009) Stanley Cohen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis

(2009) Mary G. Boy et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Structural and functional analysis of a nuclear localization signal in SOCS1

(2009) Christian Koelsche et al.   MOLECULAR IMMUNOLOGY

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

Identification of a nuclear localization signal in suppressor of cytokine signaling 1

(2008) Andrea Baetz et al.   FASEB JOURNAL

Somatically acquiredJAK1mutations in adult acute lymphoblastic leukemia

(2008) Elisabetta Flex et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The JAK kinases: Not just another kinase drug discovery target

(2008) Andrew F. Wilks   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Growth hormone receptor; mechanism of action

(2007) Andrew J. Brooks et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY